Actualités AZN Capital Corp - AZN | Actions TSX Venture Exchange

Adult Patients in England and Wales to Gain Access to First-in-Class Type 2 Diabetes Treatment

Adult Patients in England and Wales to Gain Access to First-in-Class Type 2 Diabetes Treatment PR Newswire UXBRIDGE and LUTON, England, May 30...

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive...

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast...

AstraZeneca Prescription Savings Programs Help More Patients in 2009

WILMINGTON, Del., Feb. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it provided $769.6 million in savings to...

AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David...

AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program

WILMINGTON, Del., Jan. 13 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that enrollment and re-enrollment for two of its...

Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose

WILMINGTON, Del., Dec. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal...

AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured

WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at...

AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent

WILMINGTON, Del., Nov. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the...

Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients wi

Late breaking data from PLATO sub-analysis presented at the American Heart Association Scientific Sessions ORLANDO, Fla., Nov. 15...

Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego

New Approach to Treat Opioid-Induced Constipation SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral...

AstraZeneca Partners With Mercy Primary Care Center to Help Michigan Uninsured

WILMINGTON, Del., Oct. 26 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it will provide free medication to Mercy...

U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterole

WILMINGTON, Del., Oct. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the U.S. Food and Drug Administration (FDA...

Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Tria

Significant effects shown with no increase in major bleeding compared to clopidogrel in head-to-head trial SAN FRANCISCO, Sept. 24...

AstraZeneca Among Working Mother Magazine's 2009 'Best Companies'

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) has been recognized as one of the 2009 Working Mother 100 Best...

AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve

WILMINGTON, Del., Sept. 17 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) accepted the 2009 Secretary of Defense Employer Support Freedom...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AZN Capital Corp (AZN)

Votre Hub pour des idées et discussions en direct en temps réel

AZN Actualités

Adult Patients in England and Wales to Gain Access to First-in-Class Type 2 Diabetes Treatment

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive...

AstraZeneca Prescription Savings Programs Help More Patients in 2009

AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009

AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program

Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose

AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured

AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent

Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients wi

Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego

AstraZeneca Partners With Mercy Primary Care Center to Help Michigan Uninsured

U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterole

Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Tria

AstraZeneca Among Working Mother Magazine's 2009 'Best Companies'

AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AZN Capital Corp (AZN) Actualités

AZN Capital Corp (AZN)

Votre Hub pour des idées et discussions en direct en temps réel

AZN Actualités

Adult Patients in England and Wales to Gain Access to First-in-Class Type 2 Diabetes Treatment

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive...

AstraZeneca Prescription Savings Programs Help More Patients in 2009

AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009

AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program

Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose

AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured

AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent

Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients wi

Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego

AstraZeneca Partners With Mercy Primary Care Center to Help Michigan Uninsured

U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterole

Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Tria

AstraZeneca Among Working Mother Magazine's 2009 'Best Companies'

AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application